VISIT The MS GYM!
Congratulations on stepping towards a better life with MS (or any neurological condition). The MS Gym community and resources will…
Categories
Latest Blog Posts
- Can Multiple Sclerosis Affect Your Toenails?
- MS and co-morbid autoimmunity
- CIONIC Unveils New Offerings to Address Full Spectrum of Mobility Challenges
- Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study
- A 15-year-old hockey player with MS may never experience a symptom, thanks to Colorado research
- Multiple Sclerosis: Can a Blood Test Detect MS Years Before Symptoms Appear? New Research Encouraging
- ‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’
- Breaking news: Committee favors approval of under-the-skin Ocrevus in Europe
- A Smoldering Process: A New Way of Thinking about Multiple Sclerosis
- PET scans reveal ‘smoldering’ inflammation in patients with MS
- What Are the Physiological Changes of Multiple Sclerosis (MS)?
- How to Spot the Signs of an MS Flare
- Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)
- Press Release: TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
- Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
- Apr 16, 2024 – Press Release: Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
- OrCam Assistive Smart Cameras For Impaired Sight and Reading Difficulties
- The Recording Studio Helped This MS Neurologist Through Tough Pandemic Times Now He Has a New Album to Show for It
- Foot Drop: Everything You Need To Know
- Viatris and Mapi Pharma Statement Regarding New Drug Application for GA Depot